The FDA has revised its EUA guidance for the Johnson and Johnson covid shot.
(As an unnecessary reminder, all shots available in the US are still under EUA–the ‘approved’ versions are still not available.)
It’s a pretty weak change and one of the stated reasons that they aren’t pulling it completely is to have it available if someone won’t take a gene therapy shot instead.
In any case, the stated reason for the change is those ‘rare’ blood clots that seem to be affecting a lot of folks who have taken any of the shots, not just J&J.
But a thought occurred to me.
Prefacing this with ‘I’m not a doctor or a virologist, but do try to find patterns in data that may or may not be accurate.’ And I’ve not seen drilled down information regarding the childrens’ environments or the shots that they or anyone around them might have had so this is pure supposition on my part. My tin foil hat is definitely shiny side out.
There’s been a rise in hepatitis in children and the initial thought is that it’s being caused by an adenovirus, which is the base of the J&J shot (AstraZeneca also).
Combine that with new research coming out about people who have taken any of the shots are ‘shedding’ their spike proteins .
Adenovirus trials were done in the past for gene therapy but were discontinued due to it causing massive inflammation (the patient died).
Neither company used the strain (41) that doctors found as a common factor with all of the children stricken but who’s to say that their systems didn’t go into overdrive due to exposure to the spike proteins of the other strains?
And that’s why the FDA is only (partially) shutting down J&J.
YMMV.
Midwest Chick's Place 
Leave a Reply to Anonymous Cancel reply